Controversies in Pharmacological Treatment of Inflammatory Component of Macular Edema

Author(s): Stela Vujosevic, Edoardo Midena

Journal Name: Current Pharmaceutical Design

Volume 21 , Issue 32 , 2015

Become EABM
Become Reviewer
Call for Editor


Macular edema (ME) is a common, final pathway for many different ocular and systemic diseases. The most common diseases include: diabetic retinopathy (DR), retinal vascular disorders (such as central and branch retinal vein occlusion), and uveitis. The complex and multifactorial pathophysiological mechanisms leading to ME, are still poorly understood. Inflammation plays a crucial role in the genesis of ME, as demontrsated by significant increase of different cytokines and chemokines, (besides vascular endothelial growth factors-VEGF) in ocular fluids. Currently, intravitreal steroids and anti-VEGF drugs are the most used treatments in ME of retinal vascular origin. This review will address the most important (with highest level of scientific evidence and longest followup) results on the use of intravitreal steroids and anti-VEGF drugs, starting from molecular basis to the most updated randomized clinical trials.

Keywords: Macular edema, diabetes mellitus, retinal vein occlusion, uveitis, steroids, anti-VEGF.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2015
Published on: 30 October, 2015
Page: [4688 - 4693]
Pages: 6
DOI: 10.2174/1381612821666150909095645
Price: $65

Article Metrics

PDF: 57